Loading stock data…
$3.36-0.19 (-5.35%)
Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders.
Upstream Bio, Inc. in the Healthcare sector is trading at $3.36 with a market capitalization of $291M. Wall Street consensus targets $31.14 (7 analysts), implying a +826.9% move over the next 12 months. The stock is currently near its 52-week low of $3.29, remaining 68.9% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the safe zone. Risk note: RSI 16 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $773,000↓ | $1.03M↑ | $668,000↓ | $683,000↓ | $937,000 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$42.37M↑ | -$43.62M↑ | -$46.17M↓ | -$37.83M↑ | -$44.35M |
| Net Income | -$39.70M↑ | -$40.59M↑ | -$42.46M↓ | -$33.75M↑ | -$39.97M |
Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 trials for the treatment of severe asthma and chronic rhinosi...